I don't know who would best answer this question. Perhaps it's Madame Lefebvre. It's a question about off-label use.
I don't want to discourage off-label use. I think Dr. Haggie gave a perfect example of how it evolves and why in some instances it's good. But then we see extreme cases where there may be very good off-label use, but you wonder how fast that information can be made available or the research be done so that it can become a regular treatment.
I read the piece in Maclean's magazine a short time ago about a cancer drug that had been used for macular degeneration, and was quite successful, but that thing is gone. The clinical research hadn't been done for wide distribution or wide use.
Will the changes at Health Canada to progressive licensing have a positive effect on being able to integrate different uses for drugs that are labelled for one reason now?